摘要
目的:为我国制药企业在产业升级的过程中尽量避免可能遭遇的问题提供参考。方法:通过收集近年来印度制药企业在产业升级过程中遇到障碍的一些案例,分析其中的原因并对我国制药企业产业升级提出建议。结果与结论:我国制药企业可能要面临专利挑战困难、药品质量事故频发、市场定位不妥和仿创资源分配不平衡等4个比较重大的障碍。建议我国的制药企业在专利问题上与跨国制药公司合作,着眼更高标准的药品质量管理,建立长远海外市场规划,并合理分配仿创资源。
OBJECTIVE： To provide suggestions regarding how to avoid possible problems during the process of entering international market and improving innovation ability. METHODS： Based on collected cases of obstructions that some Indian producers encountered during the process of industry upgrade in recent years and reasons of these obstructions. Some suggestions for Chinese pharmaceutical enterprises were provided. RESULTS ＆ CONCLUSIONS： Patent dispute, drug quality accidents, inaccurate market positioning and uneven recourses distributions are four major obstructions for Chinese generic drug producers. It is suggested that Chinese pharmaceutical enterprises should cooperate with multi-national pharmaceutical companies regarding patent issues, pay attention to drug quality monitoring during drug manufacturing, focus on long-term aboard market share, and balance resource distri- bution between imitation and innovation departments inside enterprises.
出处
《中国药房》
CAS
CSCD
北大核心
2011年第33期3076-3078,共3页
China Pharmacy
基金
澳门大学RC项目(UL016/09-Y1/CMS/WYT01/ICMS)
关键词
制药企业
产业升级
发展中国家
印度
中国
Pharmaceutical enterprise
Industry upgrade
Developing country
India
China
